Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.

Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.

Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1.

PMID:
30276451
2.

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.

J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5.

3.

A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.

Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, Kubo T, Harada D, Fujimoto N, Nakanishi M, Umeno T, Okada T, Chikamori K, Yamagishi T, Ohashi K, Ichihara E, Takigawa N, Tanimoto M, Kiura K.

Lung Cancer. 2017 Oct;112:188-194. doi: 10.1016/j.lungcan.2017.08.010. Epub 2017 Aug 12.

PMID:
29191594
4.

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.

Kozuki T, Chikamori K, Surleac MD, Micluta MA, Petrescu AJ, Norris EJ, Elson P, Hoeltge GA, Grabowski DR, Porter ACG, Ganapathi RN, Ganapathi MK.

Nucleic Acids Res. 2017 Jun 2;45(10):5995-6010. doi: 10.1093/nar/gkx325.

5.

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.

Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K.

Ann Oncol. 2017 Feb 1;28(2):285-291. doi: 10.1093/annonc/mdw621.

6.

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T.

Int J Clin Oncol. 2017 Feb;22(1):79. doi: 10.1007/s10147-016-1052-3. No abstract available.

7.

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T.

Int J Clin Oncol. 2017 Feb;22(1):70-78. doi: 10.1007/s10147-016-1039-0. Epub 2016 Sep 22. Erratum in: Int J Clin Oncol. 2017 Feb;22(1):79.

8.

Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).

Kanatsuka A, Sato Y, Kawai K, Hirao K, Kobayashi M, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group (JDDM), Abe N, Arai K, Fujiya H, Fukumoto Y, Dake F, Iizumi T, Ito M, Iwasaki K, Kanamori A, Kato S, Kato M, Kawara A, Kimura K, Chikamori K, Iemitsu K, Kou S, Kudo M, Kurihara Y, Lee G, Tsuruoka A, Manda N, Matoba K, Hayashi H, Minami M, Kuribayashi N, Miyazawa K, Chiba Y, Osonoi T, Nakamura S, Sasaki H, Komori K, Oishi M, Okada A, Okuguchi F, Yanagisawa M, Sugimoto H, Sugiyama H, Takai M, Takaki M, Takamura H, Takeda H, Takeda H, Tanaka K, Miwa T, Tomonaga O, Taguchi M, Yamazaki K, Wada T, Yagi N, Yamaoka K, Yuhara A.

J Diabetes Investig. 2016 May;7(3):386-95. doi: 10.1111/jdi.12430. Epub 2015 Nov 12.

9.

Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.

Nishio M, Goto K, Chikamori K, Hida T, Katakami N, Maemondo M, Ohishi N, Tamura T.

Clin Lung Cancer. 2016 Jan;17(1):24-9.e1. doi: 10.1016/j.cllc.2015.07.001. Epub 2015 Jul 29.

10.

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.

J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434.

11.

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).

Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Fukuyama T, Tamura T.

Lung Cancer. 2013 Oct;82(1):109-14. doi: 10.1016/j.lungcan.2013.07.003. Epub 2013 Jul 31.

12.

Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?

Ogata Y, Aoe K, Hiraki A, Murakami K, Kishino D, Chikamori K, Maeda T, Ueoka H, Kiura K, Tanimoto M.

Acta Med Okayama. 2011 Aug;65(4):259-63.

13.

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.

Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, Shibayama T, Kishino D, Hosokawa S, Tamaoki A, Harita S, Tabata M, Ueoka H, Shinkai T, Tanimoto M.

Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18.

14.

Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Grozav AG, Willard BB, Kozuki T, Chikamori K, Micluta MA, Petrescu AJ, Kinter M, Ganapathi R, Ganapathi MK.

Proteomics. 2011 Mar;11(5):829-42. doi: 10.1002/pmic.201000194. Epub 2011 Jan 31.

15.

DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.

Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK.

Curr Cancer Drug Targets. 2010 Nov;10(7):758-71. Review.

PMID:
20578986
16.

A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.

Chikamori K, Kishino D, Takigawa N, Hotta K, Nogami N, Kamei H, Kuyama S, Gemba K, Takemoto M, Kanazawa S, Ueoka H, Segawa Y, Takata S, Tabata M, Kiura K, Tanimoto M; Okayama Lung Cancer Study Group.

Lung Cancer. 2009 Jul;65(1):74-9. doi: 10.1016/j.lungcan.2008.10.019. Epub 2008 Dec 3.

PMID:
19056143
17.

Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.

Grozav AG, Chikamori K, Kozuki T, Grabowski DR, Bukowski RM, Willard B, Kinter M, Andersen AH, Ganapathi R, Ganapathi MK.

Nucleic Acids Res. 2009 Feb;37(2):382-92. doi: 10.1093/nar/gkn934. Epub 2008 Nov 29.

18.

Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.

Katayama H, Hiraki A, Fujiwara K, Matsuo K, Maeda T, Chikamori K, Kishino D, Tajima K, Ueoka H, Aoe K.

Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):221-4.

19.

Acute myocardial infarction in a 35-year-old postpartum woman.

Uehara K, Fujinaga H, Nakayama T, Yukinaka M, Ozaki Y, Chikamori K, Nomura M, Nakaya Y, Ito S.

J Med. 2003;34(1-6):67-79.

PMID:
17682313
20.

Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.

Chikamori K, Hill JE, Grabowski DR, Zarkhin E, Grozav AG, Vaziri SA, Wang J, Gudkov AV, Rybicki LR, Bukowski RM, Yen A, Tanimoto M, Ganapathi MK, Ganapathi R.

Leukemia. 2006 Oct;20(10):1809-18. Epub 2006 Aug 17.

PMID:
16932348
21.

Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.

Anticancer Res. 2006 May-Jun;26(3A):1869-76.

22.

Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R.

Mol Cancer Ther. 2005 Dec;4(12):1880-90.

23.

Does coronary artery stenting for acute myocardial infarction improve left ventricular overloading at the chronic stage?

Nakayama T, Nomura M, Fujinaga H, Ikefuji H, Kimura M, Chikamori K, Nakaya Y, Ito S.

Jpn Heart J. 2004 Mar;45(2):217-29.

24.

Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.

Okamoto H, Nomura M, Nakaya Y, Uehara K, Saito K, Kimura M, Chikamori K, Ito S.

Intern Med. 2003 Aug;42(8):655-64.

25.

High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction.

Uehara K, Nomura M, Ozaki Y, Fujinaga H, Ikefuji H, Kimura M, Chikamori K, Nakaya Y, Ito S.

Heart Vessels. 2003 May;18(2):67-74.

PMID:
12756602
26.

Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.

Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH, Bukowski RM, Hickson ID, Andersen AH, Ganapathi R, Ganapathi MK.

J Biol Chem. 2003 Apr 11;278(15):12696-702. Epub 2003 Feb 4.

27.

A case of papillary muscle rupture caused by acute myocardial infarction.

Morishita S, Fujinaga H, Nakayama T, Kujime S, Uehara K, Kimura M, Chikamori K, Izumi S, Nishimura T, Tano K.

J Med. 2001;32(5-6):301-9.

PMID:
11958276
28.

Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy.

Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M.

Lung Cancer. 2002 Mar;35(3):305-14.

PMID:
11844606
29.

Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.

Kohara H, Tabata M, Kiura K, Ueoka H, Kawata K, Chikamori M, Aoe K, Chikamori K, Matsushita A, Harada M.

Clin Cancer Res. 2002 Jan;8(1):287-92.

30.

[Orchiectomy for tuberculous epididymitis: a report of two cases with intractable to antituberculosis treatment].

Kunichika N, Murakami K, Makihata K, Takao K, Chikamori K, Aoe K, Miyahara N, Maeda T, Eda R, Takeyama H.

Kekkaku. 2001 Oct;76(10):673-6. Japanese.

PMID:
11712389
31.

Possible contaminant origins of the red cosmetics decorating ancient burial sites in Japan.

Yamada MO, Okayama M, Chikamori K, Yamada G, Moriwake Y, Minami T, Tohno S, Takeuchi R, Tohno Y.

Biol Trace Elem Res. 2000 Nov;77(2):149-58.

PMID:
11101047
32.

Effects of short-term pulmonary rehabilitation on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease.

Miyahara N, Eda R, Takeyama H, Kunichika N, Moriyama M, Aoe K, Kohara H, Chikamori K, Maeda T, Harada M.

Acta Med Okayama. 2000 Aug;54(4):179-84.

33.

Changes in succinate dehydrogenase (SDH) activity in Paramecium caudatum cells in culture as function of age.

Higashijima Y, Chikamori K, Sato K, Araki T.

Acta Histochem. 2000 May;102(2):231-8.

PMID:
10824615
34.

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.

Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Segawa Y, Chikamori K, Yonei T, Hiraki S, Harada M.

Br J Cancer. 1999 Feb;79(5-6):984-90.

35.

Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.

Hiraki A, Ueoka H, Yoshino T, Chikamori K, Onishi K, Kiura K, Bessho A, Mimoto J, Date H, Ando A, Shimizu N, Harada M.

Oncol Rep. 1999 Jan-Feb;6(1):75-80. Review.

PMID:
9864405
36.

Phosphohydrolytic activity in Paramecium caudatum at neutral pH.

Chikamori K, Araki T, Sato K.

Acta Histochem. 1998 Nov;100(4):395-408. Erratum in: Acta Histochem 1999 Apr;101(2):229.

PMID:
9842419
37.

[Clinical evaluation of benign asbestos pleurisy].

Kishimoto T, Okahara M, Chikamori K, Ozaki S, Aoe K, Ohke M, Fujioka H, Kimura K, Yonei T.

Nihon Kokyuki Gakkai Zasshi. 1998 Jan;36(1):18-22. Japanese.

PMID:
9611971
38.

Succinate dehydrogenase (SDH) activity in single Paramecium caudatum cells.

Chikamori K, Araki T, Sato K.

Acta Histochem. 1998 Feb;100(1):25-36.

PMID:
9542579
39.

Audiological findings of sensorineural deafness associated with a mutation in the mitochondrial DNA.

Sawada S, Takeda T, Kakigi A, Saito H, Suehiro T, Nakauchi Y, Chikamori K.

Am J Otol. 1997 May;18(3):332-5.

PMID:
9149827
40.

[Chemotherapy for small-cell lung cancer].

Ueoka H, Kiura K, Tabata M, Bessho A, Matsushita A, Chikamori K, Yamane H, Harada M, Kimura I, Ohnoshi T.

Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Dec;34 Suppl:87-91. Review. Japanese.

PMID:
9216192
41.

Free thyroxine concentrations in serum measured by equilibrium dialysis in chronic renal failure.

Okabayashi T, Takeda K, Kawada M, Kubo Y, Nakamura S, Chikamori K, Terao N, Hashimoto K.

Clin Chem. 1996 Oct;42(10):1616-20.

PMID:
8855144
42.

[The relationship between blood sugar control and vascular complications in elderly diabetic patients--investigative study in 17 hospitals of Kochi Prefecture. Kochi Working Group on Diabetes Mellitus].

Saito N, Hattori Y, Hiroi Y, Takata H, Hashimoto K, Chikamori K, Kuzuoka T, Matsumo S, Numata S, Ikeda Y, et al.

Nihon Ronen Igakkai Zasshi. 1995 Nov;32(11):747-55. Japanese.

43.

Dependence on exercise intensity of changes in electrolyte secretion from the skin sampled by a simple method.

Tanaka H, Osaka Y, Chikamori K, Yamashita S, Yamaguchi H, Miyamoto H.

Eur J Appl Physiol Occup Physiol. 1990;60(6):407-11.

PMID:
2390979
44.

Asymptomatic hyperbromidaemia detected as pseudohyperchloridaemia measured with an ion selective electrode meter.

Nagamine Y, Hamai Y, Chikamori K, Kita T, Hirota M, Oshima I, Yamashita S, Shima K.

Scand J Clin Lab Invest. 1988 Apr;48(2):177-82.

PMID:
3358097
45.

A study on enzyme adaptation pattern in postnatal rat liver in relation to activity rest cycle.

Bhattacharya RD, Chikamori K, Yamada M.

Cell Mol Biol. 1988;34(4):407-17. No abstract available.

PMID:
3219693
46.

Topographic estimations by component spectroanalysis of two formazans of nitroblue tetrazolium in tissue sections.

Araki T, Chikamori K, Sasaki K, Kawata S, Minami S, Yamada M.

Histochemistry. 1987;86(6):567-72.

PMID:
3610671
47.

In vivo and in vitro effects of angiotensin II on the release of beta-endorphin-like immunoreactivity.

Matsumura M, Inoue S, Yamanoi A, Chikamori K, Saito S.

Endocrinol Jpn. 1985 Apr;32(2):233-40.

48.

Pattern analysis of the heterogeneous distribution of succinate dehydrogenase in single rat hepatic lobules.

Chikamori K, Araki T, Yamada M.

Cell Mol Biol. 1985;31(3):217-22. No abstract available.

PMID:
4016837
49.

Alterations in the levels of beta-endorphin-like immunoreactivity in plasma and tissues of obese rats with hypothalamic lesions.

Matsumura M, Yamanoi A, Sato K, Tsuda M, Chikamori K, Mori H, Saito S.

Horm Metab Res. 1984 Feb;16(2):105-6. No abstract available.

PMID:
6323291
50.

Tridensitometric studies on mapping of succinate dehydrogenase in single gastric glands.

Yamamoto K, Takano Y, Chikamori K, Araki T, Miyata K.

Cell Mol Biol. 1983;29(5):437-42. No abstract available.

PMID:
6627304

Supplemental Content

Loading ...
Support Center